Biovitrum strengthens its relationship with Wyeth - Starts to co-promote BeneFIX® in the Nordic countries

Biovitrum strengthens its relationship with Wyeth - Starts to co-promote
BeneFIX® in the Nordic countries

Stockholm, Sweden, August 8, 2007 - Biovitrum today announced it has entered
into a new agreement, effective August 8, 2007, with Wyeth (NYSE: WYE) to
co-promote BeneFIX®, Coagulation Factor IX (Recombinant) for hemophilia B, in
the Nordic countries (Denmark, Finland, Iceland, Norway and Sweden).  With the
exception of these countries, Wyeth markets BeneFIX around the world.

Under the terms of the agreement, Biovitrum will receive a commission on BeneFIX
sales, including an additional incentive if certain sales targets are exceeded,
for a period of up to five years, with possible one year extensions thereafter.
BeneFIX uses recombinant DNA technology to replace clotting factor IX to stop or
prevent bleeding in people with hemophilia B who do not have enough factor IX of
their own.  Hemophilia B is a rare, inherited blood clotting disorder.  People
with hemophilia B are deficient in factor IX which is vital in the clotting
mechanism to prevent bleeding.  Hemophilia B is characterized by spontaneous
hemorrhages or prolonged bleeding, typically into joints and soft tissue. 
Patients with hemophilia B are dependent on protein replacement therapy with
factor IX.

Biovitrum has been very successful in the Nordic market for blood diseases and
will by this agreement strengthen its position with this additional product. 

Comments by Martin Nicklasson, CEO of Biovitrum:

"Blood diseases and especially hemophilia is an area of great strategic
importance for us.  I am delighted that Wyeth has chosen Biovitrum as a partner
in the Nordic region for BeneFIX®.  It adds to our already strong relationship
with Wyeth in the hemophilia area and it confirms our ability to deliver value
in the market.  It also demonstrates that we are an attractive partner for
co-promoting other pharmaceutical companies products in the Nordic market.  Our
commercial activities within this field will thereby continue to grow and
generate additional revenues."

Biovitrum manufactures recombinant factor VIII used in Wyeth's ReFacto® for the
treatment and prophylaxis of hemophilia A.  Biovitrum receives royalties on
Wyeth's global ReFacto® sales as well as co-promotion revenues from the sales of
ReFacto in the Nordic countries.

About BeneFIX
BeneFIX is indicated for the control and prevention of hemorrhagic episodes in
patients with hemophilia B (congenital factor IX deficiency or Christmas
disease), including control and prevention of bleeding in surgical settings.

BeneFIX is not indicated for the treatment of other factor deficiencies (e.g.,
factors II, VII, VIII and X) nor the treatment of hemophilia A patients with
inhibitors to factor VIII, nor the reversal of coumarin-induced anticoagulation,
nor the treatment of bleeding due to low levels of liver-dependent coagulation
factors.

As with the intravenous administration of any protein product, common adverse
reactions may include headache, fever, chills, flushing, nausea, vomiting or
tiredness.  BeneFIX® may be contraindicated in patients with a known history of
hypersensitivity to hamster protein.  Allergic-type hypersensitivity reactions,
including anaphylaxis, have been reported for all factor IX products.  Patients
should be informed of the early symptoms and signs of hypersensitivity
reactions. Patients should discontinue use of the product and contact their
health care provider immediately and/or seek emergency care if any
hypersensitivity reactions occur. 

About ReFacto
ReFacto Antihemophilic Factor (Recombinant) is indicated for the control andprevention of hemorrhagic episodes and for surgical prophylaxis and for
short-term routine prophylaxis to reduce the frequency of spontaneous bleeding
episodes in patients with hemophilia A.  The effect of regular routine
prophylaxis on long-term morbidity and mortality is unknown.
As with the intravenous administration of any protein product, adverse reactions
may include headache, fever, chills, flushing, nausea, vomiting, tiredness, or
symptoms of allergic reactions.  The remote possibility exists for
hypersensitivity to non-human mammalian proteins.  Known hypersensitivity to
mouse or hamster proteins may be a contraindication to the use of ReFacto. 
Allergic reactions such as hives, itching, difficulty breathing, rapid heart
rate, light-headedness and anaphylaxis have been reported for all factor VIII
products.  Patients should discontinue use of the product and contact their
health care provider immediately and/or seek emergency care if any of these
symptoms occur.
Please see Prescribing Information for BeneFIX and ReFacto at
www.hemophiliavillage.com.





For more information, please contact:

Biovitrum AB (publ)

Martin Nicklasson, CEO
Phone: +46 8 697 20 00
[email protected] 

Anna Karin Källén, VP, Corporate Communications 
Phone: +46 8 697 20 85, Cell phone: +46 73 433 20 85
[email protected] 


About Biovitrum
Biovitrum is one of the largest biopharma companies in Europe. With operations
in Sweden and in the UK Biovitrum conducts research and develops pharmaceuticals
for unmet medical needs both for common diseases and conditions that affect
small patient populations. Biovitrum has a broad and balanced R&D portfolio with
several projects in clinical and preclinical phases for the treatment of
obesity, diabetes, inflammation and eye and blood diseases as well as a number
of well defined niche indications. Biovitrum also develops and produces
protein-based drugs on a contractual basis and markets a range of specialist
pharmaceuticals primarily in the Nordic countries. Biovitrum has revenues of
approximately SEK 1.2 billion and 550 employees. Biovitrum´s share has been
listed on the OMX Nordic Exchange since September 15, 2006. More information is
available at www.biovitrum.com .